Zobrazeno 1 - 10
of 185
pro vyhledávání: '"Samuel A, Jacobs"'
Autor:
Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, Samuel A. Jacobs, Judith Bliss, Katherine Pogue-Geile, Lucy Kilburn, Zhou Zhu, Eugene F. Schuster, Hui Xiao, Lisa Swaim, Shibing Deng, Dongrui R. Lu, Eric Gauthier, Jennifer Tursi, Dennis J. Slamon, Hope S. Rugo, Richard S. Finn, Yuan Liu
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients with breast cancer and helps determine treatment. This study compared IBCMS methods on various gene-expression platforms in PALOMA-2
Externí odkaz:
https://doaj.org/article/89451dd2a5dd43c39359872a65b6f791
Autor:
Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-13 (2024)
Abstract Background We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more dura
Externí odkaz:
https://doaj.org/article/c30874be81f04b78be67858f937fdb82
Autor:
Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/4cc93b26e3c04e74a206892c9a22fe0a
Autor:
Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-11 (2019)
Abstract Purpose The primary aim of NSABP FB-7 was to determine the pathologic complete response (pCR) rate in locally advanced HER2-positive (HER2+) breast cancer patients treated with neoadjuvant trastuzumab or neratinib or the combination and week
Externí odkaz:
https://doaj.org/article/8c6fc04f4e924176a82cabe4e3ccf226
Autor:
Katherine L. Pogue-Geile, Sai K. Maley, Rim S. Kim, Ying Wang, Roberto Salgado, Corey Lipchik, Huichen Feng, Reena S. Cecchini, Samuel A. Jacobs, Ashok Srinivasan, Eleftherios (Terry) Mamounas, Charles E. Geyer Jr, Priya Rastogi, C. Kent Osborne, Soonmyung Paik, Norman Wolmark, Peter C. Lucas, Mothaffar Rimawi
Publikováno v:
Cancer Research. 83:P1-04
Background: The primary aim of the NRG Oncology/NSABP B-52 clinical trial was to test if estrogen deprivation (ED) administered concomitantly with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP), would improve the pCR rate in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c8da7ae6e2fcddb9030f0d11adc75f1
https://doi.org/10.1158/1538-7445.sabcs22-p1-04-10
https://doi.org/10.1158/1538-7445.sabcs22-p1-04-10
Autor:
Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-2 (2020)
After the publication of this work [1] the authors have reported that in Table 3 The letter “T” in columns 5 and 7 should not be there.
Externí odkaz:
https://doaj.org/article/1224ca9686ff4ace8904fdb0d7ec7ea5
Autor:
Ron Bose, Andrea Bertotti, Samuel A. Jacobs, Livio Trusolino, John Monsey, Wei Shen, Adam C. Searleman, Giorgia Migliardi, Simonetta M. Leto, Francesca Cottino, Francesco Galimi, Naveen Jain, Shyam M. Kavuri
Supplementary Figure S1. Drug sensitivity of HER2 or KRAS mutations in soft agar colony formation assay. Supplementary Figure S2. NCI-H508 cell xenograft growth curves. Supplementary Figure S3. Neratinib sensitivity of KRAS WT and KRAS mutant colorec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29ab7e32913f3a865ca55a0d29b0a565
https://doi.org/10.1158/2159-8290.22529666
https://doi.org/10.1158/2159-8290.22529666
Autor:
Ron Bose, Andrea Bertotti, Samuel A. Jacobs, Livio Trusolino, John Monsey, Wei Shen, Adam C. Searleman, Giorgia Migliardi, Simonetta M. Leto, Francesca Cottino, Francesco Galimi, Naveen Jain, Shyam M. Kavuri
Gene sequencing and MSI Status of Patients and PDX's.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90e8013312bee71612856b5ee0dca5e6
https://doi.org/10.1158/2159-8290.22529663
https://doi.org/10.1158/2159-8290.22529663
Autor:
John T. Hamm, Louis Fehrenbacher, Adam Brufsky, P Rastogi, Sandra M. Swain, Charles E. Geyer, Norman Wolmark, Thomas B. Julian, Hanna Bandos, André Robidoux, Jonathan Polikoff, Samuel A. Jacobs, Luis Baez-Diaz, Patrick J Ward, Alexander H.G. Paterson, Robert L Carolla, Louise Provencher, Terry Mamounas
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Results from adjuvant trials evaluating 6 cycles of epirubicin-based chemotherapy regimens suggested these programs may be more effective than 4 cycles of doxorubicin-based chemotherapy. METHODS: NSABP B-36 was a phase III clinical trial ori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1db9928f7d155a3f51966a193fd6884a
https://doi.org/10.1007/s10549-021-06417-y
https://doi.org/10.1007/s10549-021-06417-y
Autor:
Katherine L Pogue-Geile, Ying Wang, Huichen Feng, Corey Lipchick, Patrick Gavin, Rim S Kim, Reena S Cecchini, Samuel A Jacobs, Ashok Srinivasan, Sandra M Swain, Eleftherios Mamounas, Charles E Geyer, Priya Rastogi, Peter C Lucas, C. Kent Osborne, Soonmyung Paik, Norman Wolmark, Mothaffar F Rimawi
Publikováno v:
Cancer Research. 82:P1-07
Background: The NRG Oncology/NSABP B-52 neoadjuvant clinical trial was conducted to test if the addition of estrogen deprivation (ED) would improve the pCR rate in HER2+/ER+ breast cancer patients (pts) treated with docetaxel, carboplatin, trastuzuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a391ca2bd222a8a9593b5c465cefb183
https://doi.org/10.1158/1538-7445.sabcs21-p1-07-04
https://doi.org/10.1158/1538-7445.sabcs21-p1-07-04